Skip to content

Study · Randomized controlled trial · n = 7 · 2026

7 results

Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.

Yeung AC, Phylactou M, Koysombat K, Tsoutsouki J, Nyunt SW, Young M, Patel AH, Daniels E, Pierret ACS, Mills EG, Comninos AN, Abbara A, Dhillo WS

European journal of endocrinology1 Aug 2026

PMID42549827 (opens in a new tab)DOI10.1093/ejendo/lvag134 (opens in a new tab)PepBankPUB-42549827
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

ObjectiveTo develop a protocol for chronic kisspeptin administration that persistently stimulates gonadotropin secretion. We evaluated the effects of acute and chronic subcutaneous kisspeptin-10 administration on reproductive hormones in healthy men to (1) characterize the acute dose--response relationship to subcutaneous kisspeptin-10 infusion, (2) assess the effects of continuous kisspeptin-10 infusion over 5 days, and (3) daily intermittent administration (8 h on, 16 h off) for 12 days.DesignRandomized, single-blinded, placebo-controlled study.MethodsOverall, 15 healthy men were recruited (study 1: n = 7, study 2: n = 4; study 3: n = 7); 12 men served as controls. Luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone were assessed during an acute 8 h dose-response subcutaneous kisspeptin-10 infusions (1.25-10.0 nmol/kg/h). Thereafter, we evaluated chronic subcutaneous administration, including continuous kisspeptin-10 infusion at 180 nmol/h for 5 days, and daily 8 h infusions at 150 nmol/h for 12 days.Results(1) Acute subcutaneous kisspeptin-10 infusions dose-dependently increased LH, FSH, and testosterone vs vehicle (P < .0001). (2) Although testosterone concentrations remained elevated after 5 days of continuous kisspeptin-10, gonadotropin concentrations were similar to vehicle. (3) Daily 8 h subcutaneous infusions over 12 days sustained increases in gonadotropins (mean LH increase: vehicle -0.16 ± 0.19; day 1: +1.68 ± 0.25; day 12: +1.14 ± 0.33, P = .003 vs vehicle). Following 12 days, gonadotropin rises were still detected after kisspeptin-10 bolus (1 nmol/kg) indicating that the kisspeptin receptor remained functional.ConclusionsWe demonstrate that chronic subcutaneous kisspeptin administration sustains gonadotropin and testosterone secretion in healthy men for 12 days. These data can inform development of chronic kisspeptin administration protocols for the treatment of reproductive disorders.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy men, acute subcutaneous kisspeptin‑10 infusions dose-dependently increased LH compared with vehicle.

    In plain wordsIn healthy men, a short kisspeptin‑10 infusion under the skin raised LH levels in a dose-dependent way compared with vehicle.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseLH after acute kisspeptin-10 infusion
    Study

    n = 7

    Comparator
    Vehicle
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1.25-10.0 nmol/kg/h · subcutaneous · 8 hAs given in this study (human).

    Source sentences

    Summary
    (1) Acute subcutaneous kisspeptin-10 infusions dose-dependently increased LH, FSH, and testosterone vs vehicle (P < .0001).
    3 context sentences
    Summary · context
    Luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone were assessed during an acute 8 h dose-response subcutaneous kisspeptin-10 infusions (1.25-10.0 nmol/kg/h).
    Summary · context
    Randomized, single-blinded, placebo-controlled study.
    Summary · context
    Overall, 15 healthy men were recruited (study 1: n = 7, study 2: n = 4; study 3: n = 7); 12 men served as controls.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy men, acute subcutaneous kisspeptin‑10 infusions dose-dependently increased FSH compared with vehicle.

    In plain wordsIn healthy men, a short kisspeptin‑10 infusion under the skin raised FSH levels in a dose-dependent way compared with vehicle.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseFSH after acute kisspeptin-10 infusion
    Study

    n = 7

    Comparator
    Vehicle
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1.25-10.0 nmol/kg/h · subcutaneous · 8 hAs given in this study (human).

    Source sentences

    Summary
    (1) Acute subcutaneous kisspeptin-10 infusions dose-dependently increased LH, FSH, and testosterone vs vehicle (P < .0001).
    3 context sentences
    Summary · context
    Luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone were assessed during an acute 8 h dose-response subcutaneous kisspeptin-10 infusions (1.25-10.0 nmol/kg/h).
    Summary · context
    Randomized, single-blinded, placebo-controlled study.
    Summary · context
    Overall, 15 healthy men were recruited (study 1: n = 7, study 2: n = 4; study 3: n = 7); 12 men served as controls.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In healthy men, acute subcutaneous kisspeptin‑10 infusions dose-dependently increased testosterone compared with vehicle.

    In plain wordsIn healthy men, a short kisspeptin‑10 infusion under the skin raised testosterone in a dose-dependent way compared with vehicle.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseTestosterone after acute kisspeptin-10 infusion
    Study

    n = 7

    Comparator
    Vehicle
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1.25-10.0 nmol/kg/h · subcutaneous · 8 hAs given in this study (human).

    Source sentences

    Summary
    (1) Acute subcutaneous kisspeptin-10 infusions dose-dependently increased LH, FSH, and testosterone vs vehicle (P < .0001).
    3 context sentences
    Summary · context
    Luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone were assessed during an acute 8 h dose-response subcutaneous kisspeptin-10 infusions (1.25-10.0 nmol/kg/h).
    Summary · context
    Randomized, single-blinded, placebo-controlled study.
    Summary · context
    Overall, 15 healthy men were recruited (study 1: n = 7, study 2: n = 4; study 3: n = 7); 12 men served as controls.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In healthy men, daily 8 h subcutaneous kisspeptin‑10 infusions over 12 days sustained increases in gonadotropins; the mean LH increase was +1.14 at day 12 versus -0.16 with vehicle (P = .003).

    In plain wordsIn healthy men, daily 8-hour kisspeptin‑10 infusions for 12 days kept gonadotropin levels raised compared with vehicle.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseLH after daily 8 h kisspeptin-10 infusions for 12 days
    Study

    n = 7

    Comparator
    Vehicle
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    150 nmol/h · subcutaneous · 12 daysAs given in this study (human).

    Source sentences

    Summary
    (3) Daily 8 h subcutaneous infusions over 12 days sustained increases in gonadotropins (mean LH increase: vehicle -0.16 ± 0.19; day 1: +1.68 ± 0.25; day 12: +1.14 ± 0.33, P = .003 vs vehicle).
    3 context sentences
    Summary · context
    Thereafter, we evaluated chronic subcutaneous administration, including continuous kisspeptin-10 infusion at 180 nmol/h for 5 days, and daily 8 h infusions at 150 nmol/h for 12 days.
    Summary · context
    Randomized, single-blinded, placebo-controlled study.
    Summary · context
    Overall, 15 healthy men were recruited (study 1: n = 7, study 2: n = 4; study 3: n = 7); 12 men served as controls.
  5. 05HumanRandomized controlled trialMechanism

    In healthy men after 12 days of kisspeptin‑10, gonadotropin rises were still detected after a kisspeptin‑10 bolus, indicating the receptor remained functional.

    In plain wordsIn healthy men, after 12 days of kisspeptin‑10, a new dose still raised gonadotropins, so the receptor kept working.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseGonadotropin response to kisspeptin-10 bolus after 12 days
    Study

    n = 7

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    1 nmol/kg bolusAs given in this study (human).

    Source sentences

    Summary
    Following 12 days, gonadotropin rises were still detected after kisspeptin-10 bolus (1 nmol/kg) indicating that the kisspeptin receptor remained functional.
    2 context sentences
    Summary · context
    Randomized, single-blinded, placebo-controlled study.
    Summary · context
    Overall, 15 healthy men were recruited (study 1: n = 7, study 2: n = 4; study 3: n = 7); 12 men served as controls.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In healthy men, testosterone concentrations remained elevated after 5 days of continuous subcutaneous kisspeptin‑10.

    In plain wordsIn healthy men, testosterone stayed raised after five days of continuous kisspeptin‑10 under the skin.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseTestosterone after 5 days of continuous kisspeptin-10
    Study

    n = 4

    Comparator
    Vehicle
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    180 nmol/h · subcutaneous · 5 daysAs given in this study (human).

    Source sentences

    Summary
    Although testosterone concentrations remained elevated after 5 days of continuous kisspeptin-10, gonadotropin concentrations were similar to vehicle.
    3 context sentences
    Summary · context
    Thereafter, we evaluated chronic subcutaneous administration, including continuous kisspeptin-10 infusion at 180 nmol/h for 5 days, and daily 8 h infusions at 150 nmol/h for 12 days.
    Summary · context
    Randomized, single-blinded, placebo-controlled study.
    Summary · context
    Overall, 15 healthy men were recruited (study 1: n = 7, study 2: n = 4; study 3: n = 7); 12 men served as controls.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In healthy men, gonadotropin concentrations after 5 days of continuous subcutaneous kisspeptin‑10 were similar to vehicle.

    In plain wordsIn healthy men, LH and FSH levels after five days of continuous kisspeptin‑10 were similar to vehicle.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeGonadotropins after 5 days of continuous kisspeptin-10
    Study

    n = 4

    Comparator
    Vehicle
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    180 nmol/h · subcutaneous · 5 daysAs given in this study (human).

    Source sentences

    Summary
    gonadotropin concentrations were similar to vehicle.
    3 context sentences
    Summary · context
    Thereafter, we evaluated chronic subcutaneous administration, including continuous kisspeptin-10 infusion at 180 nmol/h for 5 days, and daily 8 h infusions at 150 nmol/h for 12 days.
    Summary · context
    Randomized, single-blinded, placebo-controlled study.
    Summary · context
    Overall, 15 healthy men were recruited (study 1: n = 7, study 2: n = 4; study 3: n = 7); 12 men served as controls.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.